Best practices in bioassay development to support registration of biopharmaceuticals
| Autor: | John R White, Marla Abodeely, Sammina Ahmed, Gaël Debauve, Evan Johnson, Debra M Meyer, Ned M Mozier, Matthias Naumer, Alessandra Pepe, Isam Qahwash, Edward Rocnik, Jeffrey G Smith, Elaine SE Stokes, Jeffrey J Talbot, Pin Yee Wong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | BioTechniques, Vol 67, Iss 3, Pp 126-137 (2019) |
| Druh dokumentu: | article |
| ISSN: | 1940-9818 0736-6205 98004301 |
| DOI: | 10.2144/btn-2019-0031 |
| Popis: | Biological activity is a critical quality attribute for biopharmaceuticals, which is accurately measured using an appropriate relative potency bioassay. Developing a bioassay is a complex, rigorous undertaking that needs to address several challenges including modelling all of the mechanisms of action associated with the biotherapeutic. Bioassay development is also an exciting and fast evolving field, not only from a scientific, medical and technological point of view, but also in terms of statistical approaches and regulatory expectations. This has led to an industry-wide discussion on the most appropriate ways to develop, validate and control the bioassays throughout the drug lifecycle. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|